JP2014534976A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534976A5
JP2014534976A5 JP2014540459A JP2014540459A JP2014534976A5 JP 2014534976 A5 JP2014534976 A5 JP 2014534976A5 JP 2014540459 A JP2014540459 A JP 2014540459A JP 2014540459 A JP2014540459 A JP 2014540459A JP 2014534976 A5 JP2014534976 A5 JP 2014534976A5
Authority
JP
Japan
Prior art keywords
ethyl
quinolin
pyridin
thieno
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014540459A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534976A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/072150 external-priority patent/WO2013068470A1/en
Publication of JP2014534976A publication Critical patent/JP2014534976A/ja
Publication of JP2014534976A5 publication Critical patent/JP2014534976A5/ja
Pending legal-status Critical Current

Links

JP2014540459A 2011-11-09 2012-11-08 ホスホジエステラーゼ10a型の阻害薬 Pending JP2014534976A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557874P 2011-11-09 2011-11-09
US61/557,874 2011-11-09
PCT/EP2012/072150 WO2013068470A1 (en) 2011-11-09 2012-11-08 Inhibitors of phosphodiesterase type 10a

Publications (2)

Publication Number Publication Date
JP2014534976A JP2014534976A (ja) 2014-12-25
JP2014534976A5 true JP2014534976A5 (OSRAM) 2016-02-12

Family

ID=47178004

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540459A Pending JP2014534976A (ja) 2011-11-09 2012-11-08 ホスホジエステラーゼ10a型の阻害薬

Country Status (26)

Country Link
US (3) US20130116241A1 (OSRAM)
EP (1) EP2776418B1 (OSRAM)
JP (1) JP2014534976A (OSRAM)
KR (1) KR20140097318A (OSRAM)
CN (1) CN104053654A (OSRAM)
AR (1) AR088801A1 (OSRAM)
AU (1) AU2012334074A1 (OSRAM)
BR (1) BR112014011284A2 (OSRAM)
CA (1) CA2852604A1 (OSRAM)
CL (1) CL2014001212A1 (OSRAM)
CO (1) CO7030959A2 (OSRAM)
CR (1) CR20140223A (OSRAM)
DO (1) DOP2014000097A (OSRAM)
ES (1) ES2620531T3 (OSRAM)
GT (1) GT201400089A (OSRAM)
HK (1) HK1201519A1 (OSRAM)
IL (1) IL232358A0 (OSRAM)
MX (1) MX2014005714A (OSRAM)
PE (1) PE20141938A1 (OSRAM)
PH (1) PH12014500877A1 (OSRAM)
RU (1) RU2014123316A (OSRAM)
SG (1) SG11201402142VA (OSRAM)
TW (1) TW201326153A (OSRAM)
UY (1) UY34445A (OSRAM)
WO (1) WO2013068470A1 (OSRAM)
ZA (1) ZA201402966B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9200005B2 (en) * 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EA030958B1 (ru) * 2013-05-10 2018-10-31 Джилид Аполло, Ллс Ингибиторы акк и их применение
US9988399B2 (en) 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
EA201591962A1 (ru) 2013-05-10 2016-06-30 Нимбус Аполло, Инк. Ингибиторы акк и их применение
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
US9193736B2 (en) 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
WO2014200885A1 (en) * 2013-06-11 2014-12-18 Janssen Pharmaceutica Nv PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
AP2016009521A0 (en) * 2014-04-04 2016-10-31 Lundbeck & Co As H Halogenated quinazolin-thf-amines as pde1 inhibitors
JP6626449B2 (ja) * 2014-04-23 2019-12-25 ダート・ニューロサイエンス・(ケイマン)・リミテッド PDE2阻害剤としての置換[1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物
GB201416352D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶7抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504432A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
JP2018504430A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ7阻害物質としてのキナゾリノン及びアザキナゾリノン
WO2016126929A1 (en) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
HK1255034A1 (zh) 2015-07-01 2019-08-02 Crinetics Pharmaceuticals, Inc. 生长抑素调节剂及其用途
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
EP3474846B1 (en) 2016-06-22 2022-11-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターm4のポジティブアロステリック調節因子
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
EP3534901B1 (en) 2016-11-07 2022-06-22 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
CN108084199A (zh) * 2017-06-13 2018-05-29 长沙理工大学 一种合成呋喃并[3,2-c]吡啶-4(5H)-酮衍生物的方法
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
JP7065951B2 (ja) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Pad阻害剤としての複素環式化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US11376254B2 (en) 2017-12-05 2022-07-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2019191451A1 (en) 2018-03-30 2019-10-03 Biotheryx, Inc. Thienopyrimidinone compounds
JP2024544552A (ja) * 2021-11-09 2024-12-03 ビジル・ニューロサイエンス・インコーポレイテッド ミエロイド細胞に発現するトリガー受容体2アゴニストとしてのヘテロ環化合物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03120857A (ja) * 1989-10-04 1991-05-23 Ibiden Co Ltd 電子部品塔載装置
JP3120857B2 (ja) * 1990-02-19 2000-12-25 中外製薬株式会社 新規な縮合複素環化合物とこれを用いた抗喘息剤
US5380721A (en) * 1990-09-10 1995-01-10 Sterling Winthrop Inc. Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
EP0612321B1 (en) 1991-10-09 1999-08-25 Syntex (U.S.A.) Inc. Pyrido pyridazinone and pyridazinthione compounds with pde iv inhibiting activity
CA2104060A1 (en) 1992-11-10 1994-05-11 Robert Ed Johnson Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents
CN1045962C (zh) * 1993-01-01 1999-10-27 森德克斯(美国)股份有限公司 吡啶并哒嗪酮或吡啶并哒嗪硫酮化合物,制备它的中间体,含它的药物组合物及其用途
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030166476A1 (en) 2002-01-31 2003-09-04 Winemiller Mark D. Lubricating oil compositions with improved friction properties
JP2007508241A (ja) 2003-07-31 2007-04-05 バイエル・フアーマシユーチカルズ・コーポレーシヨン Pde10a阻害剤を用いる糖尿病および関連障害の処置方法
PL1737850T3 (pl) 2004-04-19 2008-02-29 Symed Labs Ltd Nowy sposób wytwarzania linezolidu i związków pokrewnych
CA2568929A1 (en) 2004-06-07 2005-12-22 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
DE602004020812D1 (de) 2004-07-20 2009-06-04 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
MX2007002592A (es) 2004-09-03 2007-10-10 Memory Pharm Corp Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
US7511013B2 (en) 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
MX2008002207A (es) 2005-08-16 2008-03-27 Memory Pharm Corp Inhibidores de fosfodiesterasa 10.
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
BRPI0707223A2 (pt) 2006-01-27 2011-04-26 Pfizer Prod Inc compostos de derivados de aminoftalazina
MX2008010668A (es) 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
EP1991540A1 (en) 2006-02-21 2008-11-19 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US20090023756A1 (en) 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
MX2008010953A (es) 2006-02-28 2008-09-08 Amgen Inc Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
PL2057153T3 (pl) 2006-07-10 2013-01-31 H Lundbeck As POCHODNE (3-ARYLO-PIPERAZYN-1-YLOWE) 6,7-DIALKOKSYCHINAZOLINY, 6,7-DIALKOKSYFTALAZYNY i 6,7-DIALKOKSYIZOCHINOLINY
WO2008020302A2 (en) * 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
BRPI0807813A2 (pt) 2007-02-15 2014-08-05 Hoffmann La Roche 2-amino-oxazolinas como ligantes de taar1
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090062291A1 (en) 2007-08-22 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
EP2209774A1 (en) 2007-10-02 2010-07-28 Concert Pharmaceuticals Inc. Pyrimidinedione derivatives
WO2009051782A1 (en) 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
AU2008317375B2 (en) 2007-10-26 2013-02-28 Concert Pharmaceuticals, Inc. Deuterated darunavir
WO2009070583A1 (en) 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
CA2706866A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a

Similar Documents

Publication Publication Date Title
JP2014534976A5 (OSRAM)
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
US12233062B2 (en) Heterocyclic derivatives useful as SHP2 inhibitors
RU2014102962A (ru) Новые соединения-ингибиторы фосфодиэстеразы типа 10а
RU2473549C2 (ru) Пиримидиновые соединения, композиции и способы применения
JP2014506929A5 (OSRAM)
HRP20120105T1 (hr) Aminoheterociklički spojevi
AU2017277732B2 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
RU2016135637A (ru) 6-гетероарилокси- и 6-арилоксихинолин-2-карбоксамиды и их применение
KR101286323B1 (ko) 스피로-옥스인돌 화합물 및 치료제로서의 그의 용도
JP2015504057A5 (OSRAM)
US11820766B2 (en) Monoacylglycerol lipase modulators
JP2017505327A5 (OSRAM)
JP2021503004A5 (OSRAM)
JP2015522002A5 (OSRAM)
JP2021504380A5 (OSRAM)
WO2025049746A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
JP2012505895A5 (OSRAM)
JP2020522570A5 (OSRAM)
JP2015537010A5 (OSRAM)
JP2009538896A5 (OSRAM)
JP2015526395A5 (OSRAM)
JP2016500671A5 (OSRAM)
KR20130006625A (ko) Cdk4/6의 억제제로서의 피롤로피리미딘 화합물
US20170210724A1 (en) Alkynyl alcohols and methods of use